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The Journal of Immunology
A Comparative Analysis of Multiple Sclerosis–Relevant
Anti-Inflammatory Properties of Ethyl Pyruvate and
Dimethyl Fumarate
Djordje Miljkovic´,* Jana Blazevski,* Filip Petkovic´,* Neda Djedovic´,* Miljana Momcilovic´,*
Suzana Stanisavljevic´,* Bojan Jevtic´,* Marija Mostarica Stojkovic´,† and Ivan Spasojevic´‡
Dimethyl fumarate (DMF), a new drug for multiple sclerosis (MS) treatment, acts against neuroinflammation via mechanisms that
are triggered by adduct formation with thiol redox switches. Ethyl pyruvate (EP), an off-the-shelf agent, appears to be a redox
analog of DMF, but its immunomodulatory properties have not been put into the context of MS therapy. In this article, we
examined and compared the effects of EP and DMF on MS-relevant activity/functions of T cells, macrophages, microglia, and
astrocytes. EP efficiently suppressed the release of MS signature cytokines, IFN-g and IL-17, from human PBMCs. Furthermore,
the production of these cytokines was notably decreased in encephalitogenic T cells after in vivo application of EP to rats.
Production of two other proinflammatory cytokines, IL-6 and TNF, and NO was suppressed by EP in macrophages and microglia.
Reactive oxygen species production in macrophages, microglia activation, and the development of Ag-presenting phenotype in
microglia and macrophages were constrained by EP. The release of IL-6 was reduced in astrocytes. Finally, EP inhibited the
activation of transcription factor NF-kB in microglia and astrocytes. Most of these effects were also found for DMF, implying that
EP and DMF share common targets and mechanisms of action. Importantly, EP had in vivo impact on experimental autoimmune
encephalomyelitis, an animal model of MS. Treatment with EP resulted in delay and shortening of the first relapse, and lower
clinical scores, whereas the second attack was annihilated. Further studies on the possibility to use EP as an MS therapeutic are
warranted. The Journal of Immunology, 2015, 194: 2493–2503.
T
he pathophysiology of multiple sclerosis (MS) involves
two main components: inflammatory and neurodegener-
ative. Both of them are apparently tackled by dimethyl
fumarate (DMF; BG-12, Tecfidera), a drug that has been recently
approved in the United States, Australia, Canada, and the European
Union as a first-line treatment for patients suffering from relapsing
forms ofMS. Namely, DMF induces apoptosis of Th cells, shifts Th
balance toward nonpathogenic Th2 phenotype, inhibits differen-
tiation of APCs, reduces release of proinflammatory cytokines from
glial cells, and downregulates expression of adhesion molecules on
endothelial cells, thus interfering with leukocyte migration (1). In
addition, DMF protects neurons and astrocytes from inflamma-
tion- and neurodegeneration-related oxidative stress by activating
the endogenous defense system and blocking pro-oxidative cascades
(2). The activity of DMF appears to be prevalently based on redox
properties, that is, binding to thiols via Michael-type addition (3). DMF
turns off thiol redox switches on T cell membrane, whereas in neurons
and astrocytes, DMF targets specific thiol moieties, which leads to
activation of Nrf2-controled set of antioxidative enzymes, NAD(P)H:
quinine oxidoreductase 1 and glutathione-related enzymes, and
downregulation of transcription factor NF-kB (2, 4, 5). These phar-
macological strategies—targeting of redox switches to suppress T cell
activity (6–8), and activation of endogenous antioxidative system in-
stead of frequently futile application of exogenous antioxidants (9)—
are rather new and hold promise of further therapeutic relevance.
We have noted recently that ethyl pyruvate (EP) might represent
a DMF redox analog, and therefore could be of interest in MS
treatment (5). EP forms Michael-type adducts with thiols, acti-
vates Nrf2 in astrocytes, and inhibits NF-kB–dependent tran-
scription in different cell types, including LPS-stimulated BV2
(microglial) cells and macrophage-like RAW 264.7 cells (10–13).
Anti-inflammatory and neuroprotective effects of EP have been
observed in animal models of sepsis, uveitis, and asthma (14–16).
EP has been effective also against different neurologic insults,
such as ischemia/reperfusion (17), intracerebral hemorrhage-
induced brain injury (18), traumatic brain injury (19), 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (20), LPS (21), and 3-nitro-
propionic acid (22). Still, potential immunomodulatory effects of
EP that are of relevance for MS pathology and therapy have not
been examined so far.
Immune cells, as well as CNS resident cells, are important players in
the pathogenesis of MS and its animal model: experimental autoim-
mune encephalomyelitis (EAE). This model has been proved useful
in studying pathological mechanisms of MS. Also, some of the MS
therapies, including Copaxone and natalizumab, emerged from EAE
studies (23). Th phenotypes that produce IFN-g or IL-17, that is, Th1
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and Th17 cells, are considered to be the major pathogenic population
in MS and EAE (24). Their interactions with APCs, such as dendritic
cells and macrophages, both within the CNS and in lymphoid organs,
are essential for initiation and propagation of autoimmune response
directed against the CNS (25). Deregulated macrophages and microglia
largely contribute to CNS tissue destruction via generation of proin-
flammatory cytokines, NO, and reactive oxygen species (ROS) (26).
Moreover, microglia and even astrocytes might be important for the
process of Ag presentation within the CNS (25). Beyond this possi-
bility, both microglia and astrocytes appear to contribute to injury, but
also to the protection and repair of CNS tissue during pathogenesis of
MS and EAE (27, 28). Thus, the modulation of immune activity of
these cells represents an important therapeutic target in MS treatment.
The aim of this study was to compare the effects of EP and DMF
on various functions of cells that contribute to MS pathogenesis:
T cells, macrophages, microglia, and astrocytes. We examined
a battery of MS-relevant parameters: the production of proin-
flammatory cytokines (IFN-g, IL-17, IL-6, and TNF), generation
of NO and ROS, expression of Ag presentation–related molecules,
and phagocytosis. It appears that EP and DMF affected the ex-
amined parameters in a similar manner. Finally, effects of EP on
EAE in rats were examined showing that this agent alleviates the
disease.
Materials and Methods
Experimental animals and EAE induction
Dark Agouti rats (female, 2–4 mo old) were used in this study. The rats
were maintained in the animal facility of the Institute for Biological Re-
search “Sinisa Stankovic´.” Animal manipulation and experimental proce-
dures were approved by the local Ethics Committee (Institute for Bio-
logical Research “Sinisa Stankovic´”, no. 2-10/13). EAE was induced
with rat spinal cord homogenate (SCH) in PBS (50% w/v) mixed with
equal volume of CFA (Difco, Detroit, MI) and supplemented with My-
cobacterium tuberculosis (to 5 mg/ml). Animals were injected as described
previously (29). Animals were monitored daily for EAE clinical signs (c.s.)
and scored according to the following scale: 0 = no c.s.; 1 = flaccid tail; 2 =
hind-limb paresis; 3 = hind-limb paralysis; 4 = moribund state or death.
Cumulative c.s. was calculated as the sum of daily clinical scores, whereas
average c.s. was calculated as cumulative c.s. divided by the number of
days with clinically manifested EAE. Rats were treated i.p. with EP (300
mg/kg body weight; Sigma-Aldrich, St. Louis, MO) or vehicle (PBS), once
per day, starting from day 8 postimmunization.
Isolation of cells and cell cultures
Human PBMCs were isolated from fresh blood samples of healthy vol-
unteers (individuals who have been vaccinated with BCG vaccine and
against tetanus). All procedures related to the use of human blood are in
conformity with the recommendation provided in the Code of Ethics of the
WorldMedical Association (Declaration of Helsinki). PBMCs were purified
by centrifugation on Histopaque 1077 (Sigma-Aldrich), according to the
manufacturer’s instructions. The cells were seeded at 1 3 106/ml in 24-
well plates (Sarstedt, N€umbrecht, Germany). Draining lymph node cells
(DLNCs) were isolated from rats immunized with guinea pig myelin basic
protein (50 mg/rat; kind gift from Professor Alexander Fl€ugel, University
of Go¨ttingen, Go¨ttingen, Germany), emulsified with equal volume of CFA.
The animals were injected intradermally into hind footpads with 100 ml
MBP + CFA. The isolation took place 7 d postimmunization. In some
experiments, rats were treated with EP (Sigma-Aldrich) or vehicle (PBS),
once per day (i.p., 150 mg/kg body weight), starting from the day of im-
munization. DLNCs were cultured in RPMI 1640 culture medium (PAA
Laboratories, Pasching, Austria) that was supplemented with 2% rat serum.
The cells were seeded at 53 106/ml in 24-well plates. Spinal cord immune
cells (SCICs) were isolated from rats immunized with SCH + CFA, as
described previously (29). In brief, rats were extensively perfused with
cold PBS before spinal cord isolation. Spinal cords were homogenized and
homogenates were centrifuged using 30/70% gradient of Percoll (Sigma-
Aldrich). After centrifugation, SCICs were recovered from the Percoll
interface and washed in RPMI 1640 medium (PAA Laboratories). SCICs
were seeded at 2.5 3 106/ml in 24-well plates. In some experiments, rats
were treated with EP or vehicle, once per day (i.p., 300 mg/kg body
weight), starting from the day of immunization, and SCICs were isolated at
the peak of the disease. Resident peritoneal cells were collected by peri-
toneal lavage with 3 ml cold PBS from female rats (2–3 mo of age). The
cells were counted and seeded in RPMI 1640 culture medium supple-
mented with 5% heat-inactivated FCS (PAA Laboratories) into 24-well
plates (2 3 106/well). After 2 h of incubation at 37˚C in a humidified
atmosphere containing 5% CO2, peritoneal cells were washed two times
with PBS to remove nonadherent cells. The adherent cells were considered
as purified peritoneal macrophages (PMs). Bone marrow–derived macro-
phages (BMDMs) were isolated from female rats (2–3 mo of age) as de-
scribed previously (30). In brief, bone marrow cells were flushed from
femurs, seeded at 1 3 106/ml in 24-well plates, and grown for 7 d in the
presence of L929 cell supernatant. Adherent cells were used at the end of
this period. PM and BMDM purity were assessed by flow cytofluorometry
analysis on a CyFlow Space flow cytometer (Partec, Munster, Germany).
There was ,5% of CD3+ and CD45R+ cells in the purified populations.
Microglial BV2 cells were propagated and trypsinized for seeding in 24-
well plates (1 or 3 3 105/well). Astrocytes were isolated from mixed glial
cell cultures prepared from brains of newborn Dark Agouti rats as previ-
ously described (31). They were grown in RPMI 1640 culture medium
supplemented with glucose (4 g/l) and purified via repeated trypsinization
(0.25% trypsin and 0.02% EDTA; both from Sigma-Aldrich) and replating.
Cells were obtained after third passage and were .95% positive for glial
fibrillary acidic protein and ,3% positive for CD11b, as established by
cytofluorimetric analysis. Astrocytes were seeded in 24-well plates at
1.5 3 105/ml/well. For the treatment of cell cultures, the following reagents
were used: EP, DMF, LPS, PMA, Con A, recombinant mouse IFN-g
(Sigma-Aldrich), recombinant rat IFN-g, recombinant mouse IL-17 (R&D
Systems, Minneapolis, MN), tetanus toxoid (TT), and tuberculin purified
protein derivative (PPD; Torlak, Belgrade, Serbia). In all experiments, EP
and DMF were applied simultaneously with stimulation.
Cell viability assays
Viability of DLNCs was assessed by mitochondrial activity assay, that is,
mitochondria-dependent reduction of MTT (Sigma-Aldrich) to formazan. At
the end of the treatment, DLNCs were collected in tubes, spun down, and
supernatants were removed. Cell pellets were dissolved in 0.5 mg/ml MTT
solution and incubated for 30 min at 37˚C. Cells were centrifuged and DMSO
was added to the pellets to dissolve the formazan crystals. Crystal violet test
was applied to assess the viability of macrophages, astrocytes, and BV2 cells.
At the end of the treatment, cells were washed with PBS to remove non-
adherent dead cells, and the remaining cells were fixed with methanol. After
staining with 1% crystal violet solution, the plates were thoroughly washed and
then the dye was dissolved in 33% acetic acid. In both assays, the absorbance
of dissolved dyes, corresponding to the number of viable cells, was measured
at 540 nm with a correction at 690 nm, using an automated microplate reader
(LKB 5060-006; LKB, Vienna, Austria).
Detection of NO release and ROS generation
Nitrite accumulation, a measure of NO release, was determined in cell
culture supernatants using the Griess reaction. In brief, triplicate aliquots of
cell-free supernatants were mixed with an equal volume of Griess reagent
(1:1 mixture of 0.1% naphthylethylenediamine dihydrochloride and 1%
sulphanilamide in 5% H3PO4). The absorbance at 540 nm was determined
with a microplate reader and compared with a standard curve for NaNO2.
For detection of ROS generation, dihydrorhodamine 123 (Sigma-Aldrich)
staining was performed. The cells were pretreated with EP or DMF for
24 h, then incubated in the presence of 1 mM dihydrorhodamine 123 for
30 min and stimulated with PMA for an additional 90 min. The fluorescence
was acquired via flow cytometry.
ELISA test for determination of cytokines
Cytokine concentration in cell culture supernatants was determined by
sandwich ELISA using MaxiSorp plates (Nunc, Rochild, Denmark) and
anti-cytokine paired Abs according to the manufacturer’s instructions.
Samples were analyzed in duplicates for murine TNF, murine IL-6, rat IL-6,
rat IFN-g (R&D Systems), rat TNF (BD Biosciences, San Diego, CA),
and murine/rat IL-17 (eBioscience, San Diego, CA). Lower limit of de-
tection was 30 pg/ml, whereas upper limit of detection was 10 ng/ml for all
of the ELISA tests performed. Samples that showed values over the upper
limit of detection were adequately diluted for the measurement. The results
were calculated using standard curves made on the basis of known con-
centrations of the appropriate recombinant cytokines.
Immunoblot
Whole-cell lysates were prepared in a solution containing 62.5 mM Tris-
HCl, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophe-
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FIGURE 1. Effects of EP and DMF on viability and
cytokine release of DLNCs and SCICs. DLNCs (A–E)
were isolated from immunized rats on day 7 post im-
munization and stimulated with MBP (10 mg/ml) for
48 h. SCICs (F–H) were isolated from immunized rats
at the peak of EAE, and they were cultivated for 48 h.
Data are presented as mean 6 SD from three inde-
pendent experiments. *p , 0.05, statistically signifi-
cant compared with medium (0) cultures. #p , 0.05,
significant difference between cultures treated with the
highest nontoxic doses of DMF and EP.
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nol blue, 1 mM phenylmethanesulfonyl fluoride or PMSF, 1 mg/ml apro-
tinin, and 2 mM EDTA (pH 6.8). Samples containing 20 mg proteins
(measured by Lowry protein assay) were electrophoresed on a 12% SDS-
polyacrylamide gel. The samples were electrotransferred to polyvinylidene
difluoride membranes at 5 mA/cm2, using semidry blotting system (Fast-
blot B43; Biorad, Muenchen, Germany). The blots were blocked with 5%
w/v nonfat dry milk in PBS with 0.1% Tween 20 and probed with specific
Abs for phosphorylated IkB and b-actin (Cell Signaling Technology,
Boston, MA), followed by incubation with the secondary Ab (ECL donkey
anti-rabbit HRP-linked; GE Healthcare, Buckinghamshire, U.K.). Detec-
tion was performed by the chemiluminescence (ECL; GE Healthcare), and
photographs were made by X-ray films (Kodak, Rochester, NY). Densi-
tometry was performed with Scion Image Alpha 4.0.3.2 (Scion Corpora-
tion, Frederick, MD).
Cytofluorometry for detection of cell-surface and intracellular
markers, apoptosis, and phagocytosis
Cells were stained with PE-conjugated anti-CD4, FITC-conjugated anti-
CD11b, anti-CD40, and anti-CD134 (OX40) (BD Biosciences), FITC-
conjugated anti-CD8, anti-CD62L, anti-CD25, anti-CD80 and PE-
conjugated anti-CD86 (AbD Serotec, Oxford, U.K.), and PE-conjugated
anti-F4/80 and anti–MHC class II Abs (eBioscience). Foxp3 staining
was performed according to procedure suggested by the manufacturer
(eBioscience). Appropriate isotype control Abs were used where necessary
to set gates for cell marker positivity. Typically, proportion of isotype
control Ab-stained cells was ,1%. Detection of apoptosis of DLNCs was
performed via Annexin V-FITC staining (Biotium, Hayward, CA). Cells
positive for Annexin V-FITC were considered apoptotic. For detection of
phagocytosis, BV2 cells were plated in 24-well plates at 1 3 105/well and
incubated at 37˚C for 1 h. Latex beads (1 mm, yellow-green; Sigma-
Aldrich) were preopsonized in PBS supplemented with 50% FCS. The
preopsonized beads were added to BV2 cells (10 beads/cell), and cells
were incubated at 37˚C for an additional hour in the presence of appro-
priate treatments. BV2 cells were trypsinized for cytofluorometry (Partec
CyFlow Space cytometer). Results of cytofluorometry are presented as
proportion of cells bound by an appropriate Ab or as mean fluorescent
intensity of cell population.
EPR spectroscopy
Electron paramagnetic resonance (EPR) assay for free thiols was applied to
establish the affinity of DMF and EP for thiol groups. In brief, reduced
glutathione (GSH; 50 mM; Merck, Darmstadt, Germany) was incubated for
2 min with different concentrations of EP or DMF (0–5 mM range) in PBS
(pH 7.4). Then thiol-sensitive biradical spin probe RSSR (Enzo Life Sci-
FIGURE 2. Effects of EP and DMF on viability and
cytokine and NO production in stimulated macrophages.
PMs (A–D) and BMDMs (E–H) were stimulated with LPS
(100 ng/ml) for 24 h. Mean values 6 SD from three in-
dependent experiments are presented. *p , 0.05, statisti-
cally significant compared with medium (0) cultures. #p ,
0.05, significant difference between cultures treated with
the highest nontoxic dose of DMF and EP.
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ences International, Plymouth Meeting, PA) dissolved in DMSO was
added to a final concentration of 100 mM. This probe forms an adduct with
thiol groups and gives a characteristic EPR spectrum that is used for the
quantification of free thiol groups (32). Samples were placed in Teflon
tubes with a wall thickness of 0.025 mm and an internal diameter of 0.6 mm
(Zeus Industries, Raritan, NJ) and inserted into quartz capillaries. EPR
spectra were recorded after 4-min incubation (total) using a Varian E104-A
EPR spectrometer operating at X-band (9.51 GHz), EW software (Scien-
tific Software, Bloomington, IL), and the following settings: modulation
amplitude, 1 G; modulation frequency, 100 kHz; microwave power, 10 mW;
scanning time, 2 min. The concentration of free thiol groups was determined
via calibration curve that was prepared using different concentrations of
GSH (without DMF or EP).
The ability of EP and DMF to scavenge superoxide radical anion was
examined using SOTS-1 (Cayman Chemicals, Ann Arbor, MI), a thermal
source of superoxide. SOTS-1 was dissolved in DMSO and supplemented
(0.2 mM final concentration) to PBS containing spin trap 5-diethox-
yphosphoryl-5-methyl-1-pyrroline-N-oxide (DEPMPO; 10 mM; Enzo Life
Sciences International) and diethylene triamine pentaacetic acid (1 mM;
chelating agent, added to suppress redox activity of transition metals im-
purities). This system was incubated at 37˚C for 5 min in the absence
(control system) or the presence of EP (1 or 10 mM) or DMF (1 mM). EPR
spectra were acquired 2 min after. The ability of EP and DMF to scavenge
hydroxyl radicals (•OH) was tested using the Fenton reaction as an •OH-
producing system (Fe2+ + H2O2 → Fe
3+ + OH2 + •OH). The Fenton re-
action was performed by combining H2O2 (1 mM; Carlo Erba Reagents,
Milan, Italy) and FeSO4 (0.2 mM; Merck) in the absence or the presence of
EP (1 or 10 mM) or DMF (1 mM). DEPMPO was added before H2O2 at
the final concentration of 10 mM. The period between the initiation of
reaction and EPR measurements was 2 min. In EPR spin-trapping ex-
periments, spectra were recorded using the following settings: modulation
amplitude, 2 G; modulation frequency, 100 kHz; microwave power, 10 mW;
scanning time, 4 min. Signal intensities were established by simulation
and double integration that were performed using WINEPR SimFonia
Computer Program (Bruker Analytische Messtechnik GmbH, Karlsruhe,
Germany) and previously described simulation parameters (33). Rela-
tive inhibition of free radical production was calculated as follows: (IControl2
IDMF or EP)/IControl 3 100, where I is the intensity of EPR spectrum obtained
in controls, or samples with EP or DMF.
Statistical analysis
The results are presented as mean 6 SD of values obtained in repeated
experiments. A Student t test (two-tailed) was performed for statistical
analysis. A p value ,0.05 was considered statistically significant.
Results
Effects on DLNCs and SCICs
Fig. 1 shows comparison of in vitro effects of EP and DMF on
DLNCs that were isolated from rats 7 d after immunization with
MBP + CFA and restimulated with MBP in vitro. Significant in-
hibition of DLNC viability emerged at concentrations of 12.5 mM
and 400 mM for EP and DMF, respectively (Fig. 1A). The levels of
various cytokines were determined in supernatants of DLNCs
treated with EP and DMF at concentrations that did not signifi-
cantly affect viability. EP reduced the release of IFN-g (Fig. 1B)
and TNF (Fig. 1D). It had no effect on IL-17 production (Fig. 1C),
and affected IL-10 release only at the highest concentration tested
(Fig. 1E). DMF decreased IFN-g and IL-17 release (Fig. 1B, 1C)
and did not show significant effects on TNF and IL-10 (Fig. 1D,
1E). Fig. 1 also shows in vitro effects of EP on SCICs isolated
from rats at the peak of EAE (12–14 d post immunization). Al-
though EP exerted limited effect on SCIC viability (Fig. 1F), it
potently inhibited IFN-g and IL-17, but not IL-10 and TNF,
production in these cells (Fig. 1G, 1H). Thus, EP is efficient in the
reduction of release of important effector cytokines from in vitro
and in vivo reactivated T cells.
Effects on macrophages
Fig. 2 shows the effects of EP and DMF on PMs and BMDMs that
were isolated from healthy rats and stimulated with LPS. Both
compounds had significant, yet limited inhibitory effects on PM
viability at almost all applied concentrations (Fig. 2A). Toxic
effects of EP and DMF on BMDMs were more noticeable and
emerged at 12.5 mM and 80 mM, respectively (Fig. 2E). Both
compounds had profound inhibitory effects on the release of
proinflammatory cytokines IL-6 and TNF in PMs (Fig. 2B, 2C)
and BMDMs (Fig. 2F, 2G). Also, EP and DMF inhibited NO re-
lease in both types of macrophages (Fig. 2D, 2H). Further ana-
lyses were performed using EP and DMF concentrations that did
not affect the viability of PMs and BMDMs. It can be observed
that EP, as well as DMF, suppressed ROS production in PMs
(Fig. 3A) and BMDMs (Fig. 3D). Also, we examined the effects of
EP and DMF on MHC class II, CD80, CD86, and CD11b ex-
pression in PMs and BMDMs. EP and DMF significantly reduced
proportion of macrophages expressing MHC class II molecules
and downregulated CD11b expression in PMs (Fig. 3B, 3C) and
BMDMs (Fig. 3E, 3F). The proportion of cells expressing CD80
and CD86 was not affected (data not shown).
Effects on microglia
EP was not toxic to microglial cells even at a concentration of 25
mM, whereas DMF affected the viability at concentrations as low
as 80 mM (Fig. 4A). In the noncytotoxic concentration range, EP
showed considerably pronounced effects on the release of IL-6
and TNF from IFN-g + LPS–stimulated BV2 cells, compared
with DMF (Fig. 4B, 4C). EP was superior to DMF in inhibiting
NO release as well (Fig. 4D). Further analyses were performed on
BV2 cells treated with EP and DMF at nontoxic concentrations.
Neither EP nor DMF inhibited ROS generation (Fig. 5A).
Phagocytosis was significantly reduced in BV2 cells by EP, but not
FIGURE 3. Effects of EP and DMF on ROS generation and MHC class
II and CD11b expression in stimulated macrophages. PMs (A–C) and
BMDMs (D–F) were stimulated with LPS (100 ng/ml) for 24 h. For ROS
detection, cells were additionally stimulated with PMA (400 ng/ml). Mean
values 6 SD from three independent experiments are presented. *p ,
0.05, statistically significant compared with medium (0) cultures.
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by DMF (Fig. 5B). The effects of EP and DMF on NF-kB acti-
vation in IFN-g + LPS–stimulated microglial cells were deter-
mined via detection of phosphorylated, that is, inactivated NF-kB
inhibitory molecule, IkB. It can be observed that both EP and
DMF inhibited NF-kB activation via increasing the level of active
IkB, yet the effects of EP were significantly more pronounced
compared with DMF (Fig. 5C). Finally, EP, and to a lesser extent
DMF, reduced the proportion of BV2 cells expressing activation
markers CD40 and F4/80 (Fig. 5D).
Effects on astrocytes
It appears that both compounds were more toxic to astrocytes
compared with other cell types investigated in this study. However,
whereas toxic doses of EP were in the millimolar range (.6.25
mM), those of DMF were in micromolar range (#16 mM;
Fig. 6A). Level of a proinflammatory cytokine IL-6 was reduced
in the cell cultures treated with concentrations of EP or DMF that
did not affect astrocyte viability (Fig. 6B). Last, only EP provoked
significant inhibition of NF-kB activation by suppressing IkB
phosphorylation (Fig. 6C). In summary, EP is less toxic than DMF
to astrocytes in vitro, and it blocks IL-6 generation and NF-kB
activation in these cells.
Thiol-binding and antioxidative capacities
An EPR spin-probing assay was applied to examine capacities of
EP and DMF to form thiol adducts. The steeper concentration-
adduct formation curve for DMF compared with EP implies
that DMF has a higher affinity for thiols (Fig. 7A). Besides
thiol-adducts–mediated activation/inhibition of complex cellular
responses, EP and DMF might act as blunt antioxidants. In line
with this, we examined their capacities to scavenge two patho-
logically most relevant-free radicals: superoxide and hydroxyl
radical. For this purpose, specific generating systems and spin-
trapping method were applied. In this technique, an EPR “silent”
FIGURE 4. Effects of EP and DMF on viability (A), cytokine (B and C),
and NO (D) production in stimulated BV2 cells. BV2 cultures were
stimulated with LPS (100 ng/ml) and IFN-g (10 ng/ml) for 24 h. Mean
values 6 SD from three independent experiments are presented. *p ,
0.05, statistically significant compared with medium (0) cultures. #p ,
0.05, significant difference between cultures treated with the highest
nontoxic dose of DMF and EP.
FIGURE 5. Effects of EP and DMF on stimulated BV2 cells. ROS
production (cells were additionally stimulated with 400 ng/ml PMA) (A),
phagocytosis (B), the level of phosphorylated IkB (C), and expression
of CD40 and F4/80 (D) were determined in cells stimulated with LPS
(100 ng/ml) and IFN-g (10 ng/ml) in the absence or the presence of EP
(12.5 mM) or DMF (16 mM) for 24 h. Mean values 6 SD from three
independent experiments are presented. *p , 0.05, statistically significant
compared with medium (0) cultures. #p , 0.05, significant difference
between cultures treated with DMF and EP.
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compound, spin trap (DEPMPO in this study), is added to the
sample to react with radicals and form stable EPR active spin
adducts exhibiting characteristic EPR spectra. A decrease in the
intensity or EPR signal stands for a lower level of free radicals
in the system. Fig. 7B shows that DMF at 1 mM (well above the
cytotoxic level) drastically decreased EPR signal of DEPMPO
adduct with superoxide. EP showed modest effects at the same
concentration but reached antioxidative performance of DMF at
10-fold higher concentration. A very similar setup was observed
for hydroxyl radical, that is, the ability of DMF to remove this
ROS was ∼10-fold more pronounced compared with EP (Fig. 7C).
Effects on EAE in rats
Rats were immunized with SCH + CFA and treated once per day
with EP (300 mg/kg) or vehicle (eight animals per group) starting
1 d before the expected clinical onset of the disease until the end of
the first relapse (day 17). Whereas control (vehicle-treated) rats
developed full-blown EAEwith a strong first attack and consequent
relapse of the disease, EP-treated rats had a mild first attack and no
relapse until the end of the observation period (day 40 post im-
munization; Fig. 8A). EAE started earlier and lasted longer in the
control group, whereas cumulative c.s., maximal c.s., and average
c.s. were significantly lower in the EP-treated group (Table I). A
drastically lower number of SCICs was obtained from whole
spinal cord isolates of EP-treated rats (0.71 6 0.25 3 106) com-
pared with vehicle-treated rats (2.03 6 0.29 3 106). Furthermore,
SCICs from EP-treated animals produced less IL-17 than corre-
sponding cells isolated from the control rats (Fig. 8B). Finally, the
effects of in vivo application of EP in the inductive phase of EAE
on cytokine generation in DLNCs were examined. There was
a slight but nonsignificant decrease in the number of DLNCs that
were isolated from EP-treated (31.9 6 13.7 3 106/DLN) com-
pared with control rats (36.6 6 13.4 3 106/DLN). Further, there
was no difference in the viability of DLNCs isolated from EP-
treated and vehicle-treated rats after 48 h of cultivation in the
absence or presence of MBP as determined by MTT test (data not
shown). However, DLNCs isolated from EP-treated rats produced
significantly less IFN-g and IL-17 in MBP-stimulated and in
nonstimulated cultures (Fig. 8C). TNF and IL-10 release ex vivo
was not affected by EP in neither SCICs nor DLNCs. Frequencies
of various cellular populations among DLNCs were determined by
flow cytofluorometry (Table II). EP induced a significant increase
in the number of CD4+CD25+ cells. Still, this was not accompa-
nied by the rise in the frequency of DLNCs expressing Foxp3, the
signature marker of regulatory T cells. The proportions of other
relevant phenotypes were not significantly modulated by in vivo
treatment with EP, including the frequency of naive CD4 T cells
(CD4+CD62L+) and activated CD4 T cells (CD4+OX40+). Of
note, there was no influence of EP on the frequency of apoptotic
FIGURE 6. Effects of EP and DMF on stimulated astrocytes. Viability
(A), IL-6 concentration (B), and level of pIkB (C) were determined in
astrocytes that were stimulated with IFN-g (10 ng/ml) and IL-17 (50 ng/ml)
for 24 h in the presence or the absence of EP or DMF. Mean values 6 SD
from three independent experiments are presented. *p , 0.05, statistically
significant compared with medium (0) cultures.
FIGURE 7. Redox properties of EP and DMF. The ability to bind to
thiol groups on GSH. Curves represent sigmoidal fits (A). Characteristic
EPR signals of DEPMPO adduct with superoxide in the absence or the
presence of EP or DMF (B). Characteristic EPR signals of DEPMPO ad-
duct with hydroxyl radical in the absence or the presence of EP or DMF
(C). Gray represents spectral simulations, which were applied to evaluate
signal intensities (I). Relative inhibition (RI) was calculated according to
the formula: (IControl 2 IDMF or EP)/IControl 3 100 from three independent
experiments.
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cells among DLNCs or CD4+ T cells purified from DLNCs
(Table II). In close, EP potently modulated encephalitogenic cells
within the CNS and at the periphery, and consequently alleviated
relapsing-remitting EAE in rats.
Effects on human PBMCs
Human PBMCs were stimulated with a mitogen (Con A) or with
Ags (TT or PPD) in the presence or absence of EP. Viability of
human PBMCs stimulated with Con Awas affected only at 25 mM
EP (Fig. 9A). At the same time, the production of IFN-g and IL-17
was potently inhibited by EP in concentrations that did not reduce
PBMC viability (Fig. 9B, 9C). Moreover, at the dose that was not
toxic to PBMCs (Fig. 9D), EP significantly reduced IFN-g and IL-
17 production in Ag-stimulated PBMCs (Fig. 9E, 9F).
Discussion
We showed in this study that EP and DMF have in common
a number of MS-relevant anti-inflammatory effects. Of major in-
terest in this study is the suppressed release of T cell effector
cytokines: IFN-g and IL-17. These cytokines represent the
markers of Th1 and Th17 cells, which have been considered the
major driving force of inflammation and autoimmunity in MS
(24). EP and DMF provoked a drop in macrophage release/
production of cytokines (IL-6 and TNF) and reactive species
(NO and ROS), which promote neuroinflammatory and neurode-
generative events in MS. For example, it has been shown that IL-6
potentiates the resistance of effector T cells to regulatory T cells in
MS (34), and that soluble TNF actively contributes to demyelin-
ation and axonal degeneration in EAE neuroinflammation (35).
Likewise, NO and different ROS are involved in oligodendrocytes
loss, blood–brain barrier dysfunction, T cell infiltration, and
neurodegeneration (5). The essential role of macrophages in MS
pathology via Ag presentation and epitope spreading has been
outlined recently (36). Pertinent to this, EP and DMF obstructed
MHC class II expression in macrophages. Also, the ability of EP
and DMF to scavenge ROS and to inhibit NO and ROS generation
FIGURE 8. Effects of EP on EAE. Immunized rats
were treated once per day with EP or vehicle from day
8 until day 17 post immunization (A), from day 8 to the
peak of the disease (B), or from days 0 to 7 post im-
munization (C). SCICs were isolated at the peak of the
disease, and viability and cytokine production were
determined after 48 h of cultivation (B). DLNCs were
isolated on day 7 post immunization and cultivated in
medium alone (0) or restimulated in vitro with MBP
(10 mg/ml) for 48 h (C). Mean values 6 SD from eight
rats (A) or from six rats (B and C) per group are pre-
sented. *p , 0.05, statistically significant compared
with samples of vehicle-treated rats. #p , 0.05, sig-
nificant difference between corresponding untreated (0)
and MBP-restimulated cultures.
Table I. Effects of EP on EAE parameters
Treatment Incidence (%) Onset (d) Duration (d) Cumulative c.s. Average c.s. Maximal c.s.
1st Episode
Vehicle 100.0 10.2 6 1.0 4.8 6 1.0 11.1 6 3.3 2.3 6 0.7 2.8 6 0.7
EP 87.5 12.7 6 1.0* 2.0 6 1.3* 3.9 6 3.2* 1.5 6 0.9 1.1 6 0.9*
Relapse
Vehicle 100.0 21.7 6 0.8 5.7 6 3.4 5.6 6 4.2 0.9 6 0.3 1.3 6 0.7
EP 12.5 22.3 6 0.5 0.4 6 0.8* 0.1 6 0.4* 0.1 6 0.2* 0.1 6 0.2*
Mean values 6 SD from eight rats per group are presented.
*p , 0.05, statistically significant compared with samples of vehicle-treated EAE rats.
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might add to their anti-Ag–presenting effects, as it is known that
macrophages use ROS and NO in myelin processing, whereas
reactive species appear to contribute to the generation of new
epitopes in MS (5). In addition, EP and DMF downregulated the
expression of CD11b, an adhesion molecule that is critical for the
development of EAE (37).
In IFN-g + LPS–stimulated microglial cells, EP and DMF
suppressed IL-6, TNF, and NO release, and NF-kB activation.
Importantly, the effects of EP, but not DMF emerged at concen-
trations that did not affect cell viability. Thus, the observed effects
of EP were not a consequence of fewer producers, but rather of
lowered capacity to produce the cytokines and NO. The effects of
EP on NF-kB and NO generation are most likely interlinked. It is
known that NF-kB controls the expression of inducible NO syn-
thase (iNOS) (38), and that iNOS expression can be reduced in
activated microglia via suppression of IkB phosphorylation, which
leads to NF-kB inhibition (39). Of note, our findings are in ac-
cordance with available data on the effects of DMF on IL-6, TNF,
and NO production, and the effects of EP on cytokine and NO
production, and iNOS expression in LPS-stimulated microglia
(13, 19, 40). It appears that pretreatment with EP exerts even more
potent effects on LPS-activated primary microglia (19). Further,
EP and DMF restrained microglia activation according to: 1)
lower number of cells positive for CD40 (costimulatory protein
found on APCs), 2) lower number of F4/80+ cells (a marker of
mature macrophages), and 3) suppressed phagocytosis. Microglial
cells are semiprofessional APCs, and immunomodulatory effects
observed in this article might hinder Ag presentation. In IFN-g +
IL-17–stimulated astrocytes, EP and DMF suppressed IL-6 release
Table II. Phenotypic analysis of DLNCs isolated from immunized rats
treated with EP
Control EP
CD4+ 44.3 6 3.4 40.8 6 4.2
CD8+ 15.8 6 4.9 16.9 6 1.4
CD4+CD8+ 1.9 6 0.4 1.9 6 0.5
CD4+CD62L+ 36.4 6 2.1 36.9 6 2.7
CD4+OX40+ 7.0 6 0.8 8.5 6 0.7
CD4+CD25+ 4.5 6 0.4 5.2 6 0.3*
CD4+CD25+ Foxp3+ 2.7 6 0.2 3.0 6 0.3
MHCII+ 5.3 6 1.7 5.2 6 0.9
CD80+ ND ND
MHCII+CD80+ 9.7 6 0.6 8.9 6 1.4
CD11b+ 7.5 6 0.2 8.3 6 0.8
CD86+ 0.8 6 0.1 0.9 6 0.1
CD11b+CD86+ 1.5 6 0.1 1.8 6 0.2
DLNCs (apoptotic) 12.8 6 2.8 11.8 6 3.9
CD4+ T cells (apoptotic) 16.4 6 2.6 14.8 6 4.2
Ab staining was performed immediately after isolation. Data (%) are presented as
mean 6 SD from four DLN per group.
*p , 0.05, statistically significant difference between EP and Ctrl.
ND, not detected.
FIGURE 9. Effects of EP on human PBMCs. PBMCs were isolated from healthy volunteers (1–5) and stimulated with Con A (2.5 mg/ml) for 24 h (A–C)
or with TT (2 mg/ml) or PPD (10 mg/ml) for 48 h (D–F). PBMCs did not produce measurable levels of IL-17 in response to TT. Data are presented as means6
SD from triplicate measurements. *p , 0.05, statistically significant compared with medium (0) cultures.
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and NF-kB activation. This is similar to previous reports showing
decreased IL-6 release (40) and preserved IkB inhibitory perfor-
mance in LPS-stimulated astrocytes exposed to DMF (4). The
study by Lin and coauthors (4) documented that this and other
effects of DMF are mediated via thiol-binding. In respect to this,
we showed in this study that EP shows the affinity for thiol groups
as well. Pertinent to MS, the activation of NF-kB is a well-known
feature of astrocytes in active lesions (41). It has been shown on
the cuprizone model of demyelination that the cell-specific inhi-
bition of NF-kB in astrocytes is sufficient to protect the mice from
myelin loss (42). The suppression of NF-kB activity in astrocytes
might be a very important tool in alleviating neurodegeneration.
NF-kB appears to activate a set of pro-oxidative events and self-
sustaining redox loops (38), and astrocytes have been postulated to
be the centers of oxidative stress in MS lesions (43). Finally, EP
and DMF are capable of providing a more direct antioxidative
protection via scavenging superoxide and hydroxyl radical, which
have the central place in MS-related neurodegenerative processes,
such as “slow burning” of demyelinated neurons and oxidative
damage directly inflicted by cytotoxic cells (5).
Emerging data imply that EP might be an effective anti-
inflammatory agent in vivo. In models of hypoxia-ischemia– and
LPS-provoked white matter injury, EP has significantly reduced
oligodendrocyte loss and hypomyelination, astrocytes and micro-
glia activation, and proinflammatory cytokine release (44, 45).
In an intracerebral hemorrhage-induced brain injury model, EP
protected neurons from degeneration, suppressed the activation of
microglia, and downregulated the production of TNF and IL-1b
(18). EP has shown neuroprotective capacities in a spinal cord
injury model. It inhibited astrogliosis and neuroinflammation,
promoted neuron survival and neural regeneration, and improved
the functional recovery of spinal cord (46). In addition, it has been
shown that EP attenuated matrix metalloproteinase 9 expression in
the CNS and on the periphery, blood–brain barrier breakdown,
cerebral inflammation, and secondary neuronal damage in a trau-
matic brain injury model (19). Finally, in rats with LPS-induced
inflammation (a model of sepsis), EP treatment suppressed IL-6
and TNF levels in plasma (14). In respect to MS, we showed in
this study that in vivo treatment of EAE animals with EP potently
affects the ability of MBP-specific, that is, encephalitogenic
T cells, to produce effector cytokines IFN-g and IL-17. Moreover,
EAE was markedly downregulated in rats treated with EP. It is
important to note that EAE animals were treated only during the
first relapse, that is, there was no pretreatment with EP, and the
application was stopped at the end of the episode. This treatment
modality was applied to mimic the therapy of MS patients in re-
lapse. It delivered significantly lower clinical scores, delay of EAE
onset, and shorter period of the first attack, but also annihilated
the second attack, which implies that EP has long-term anti-
inflammatory effects in EAE. Importantly, this treatment low-
ered the number and activity of immune cells within the CNS, thus
probably hampering deleterious effects of neuroinflammation.
Interestingly, although application of EP in the inductive phase of
EAE led to reduced production of both IFN-g and IL-17 in
DLNCs, the therapeutic treatment restricted only IL-17 generation
in SCICs. However, it has to be emphasized that overall produc-
tion of IFN-g within the CNS was also reduced because there were
less inflammatory cells present in spinal cords of EP-treated rats.
In line with this, both IFN-g and IL-17 production were inhibited
in SCICs in vitro. Potency of EP to inhibit synthesis of Th1 and
Th17 effector cytokines was further demonstrated in human im-
mune cells, where it was clearly shown that this agent restricted
IFN-g and IL-17 generation in polyclonal and Ag-specific re-
sponse of human PBMCs. Both in vivo effect of EP in model
animals and its in vitro effect on human cells are of relevance for
taking EP into consideration as a potential MS therapeutic.
In vitro anti-(neuro)inflammatory effects of EP emerged in the
higher concentration range compared with DMF. This also appears
to be true for in vivo settings. EP alleviated EAE in model animals
at daily doses of 300 mg/kg, whereas recommended oral main-
tenance dosage of Tecfidera for MS patients is 240 mg twice
a day (∼6 mg/kg/day). The discrepancy between the effective
concentrations/doses of EP and DMF might be explained by the
facts that: 1) EP represents a metabolic substrate, that is, intra-
cellular esterase processes EP to pyruvate that is further available
for tricarboxylic acid cycle (47); and 2) on the biochemical level,
EP showed lower capacity to form thiol-adducts and to scavenge
ROS compared with DMF. Nevertheless, the immunomodulatory
dose range of EP is still well below the cell toxicity threshold as
measured by cell viability. More importantly, EP is approved for
human use and has been enrolled in several clinical trials (11, 14).
As an illustration, in a U.S.-based clinical trial (the only finished
phase II trial on EP so far), six doses of 7.5 g EP were administered
i.v. during 36 h (360 mg/kg/day) to high-risk patients undergoing
cardiac surgery (48). Although this trial has not delivered clear
clinical benefits in the prevention of sepsis and related conditions, it
did show that EP is safe and well tolerated at high doses.
Although there are several drugs for MS treatment on the
market, none of them is the cure for the disease, and there are signi-
ficant concerns about their side effects and long-term efficacy (1).
Also, these are lifelong therapies with high prices (http://www.
healthline.com/health-news/ms-why-are-ms-drug-prices-so-high-
071913). All of these facts call upon studies on new drugs that
would overcome the common disadvantages of the existing
medications. In line with this, the aim of the recently launched
MS-Secondary Progressive Multi-Arm Randomization Trial (MS-
SMART) is the testing of three off-the-shelf drugs as possible
therapeutics for MS (http://www.ms-smart.org). The perspective for
development of redox strategy-based MS therapy is open. DMF
could be the first-in-class drug, and it appears that EP might be the
next in line. Our results speak in favor of this possibility. Maybe the
most favorable facts are that EP reduced IFN-g and IL-17 generation
in human PBMCs, alleviated EAE in rats, and even more it practi-
cally prevented the second relapse. Still, further research on animal
models is needed. Taking into account the importance of redox
component in the mechanisms of EP activity, in addition to the
widely used EAE, examinations should be focused on the model of
coronavirus-induced demyelinating encephalomyelitis. According to
a recently published study, this model reflects oxidative processes in
MS in the most appropriate way (49). In conclusion, further studies
on the possibility to use EP as a MS therapeutic are warranted.
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